Table 1.
Fraction * | Amount of Isolated Anabaenopeptin (μg) | m/z and Proposed Structure of Anabaenopeptin Components in Fractions | Anabaenopeptin Concentration in Tested Samples (µg/mL) | PP1 IC50 (ng/mL) | Carboxypeptidase A IC50 (µg/mL) | NOD Concentration in Tested Samples (ng/mL) | References |
---|---|---|---|---|---|---|---|
1(38) | 1305 | 934 Phe + CO[Lys + Val + Hty + MeHty + MetO] | 43.5 | 16 | 20 | - | [37] |
2(46) | 1287 | 844 (Anabaenopeptin A) | 42.9 | 86 | <3 | 43.4 | [6] |
Tyr + CO[Lys + Val + Hty + MeAla + Phe] | |||||||
2(48) | 273 | 844 (Anabaenopeptin A) | 9.1 | 88 | <3 | 12.9 | [6] |
Tyr + CO[Lys + Val + Hty + MeAla + Phe] | |||||||
2(50) | 129 | 900 Ile + CO[Lys + Val + Hty + MeHty + MetO] | 4.3 | 40 | <3 | 4.8 | New, this study |
934 Phe + CO[Lys + Val + Hty + MeHty + MetO] | [37] | ||||||
856 Phe + CO[Lys + Val + Val + MeHty + MetO] | New, this study | ||||||
4(50) | 1305 | 858 (Oscillamide Y) | 43.5 | 62 | 15 | 9.0 | [7] |
Tyr + CO[Lys + Ile + Hty + MeAla + Phe] | |||||||
4(51) | 1305 | 858 (Oscillamide Y) | 43.5 | 62 | 15 | - | [7] |
Tyr + CO[Lys + Ile + Hty + MeAla + Phe] | |||||||
4(52) | 51 | 870 Phe + CO[Lys + Val + Leu + MeHty + MetO] | 1.7 | 66 | - | - | New, this study |
5(39/40) | 10,914 | 884 Ile + CO[Lys + Val + Hph + MeHty + MetO] | 181.9 | 53 | <3 | - | New, this study |
6(38) | 123 | 814 Phe + CO[Lys + Val + Hty + MeGly + Phe] | 4.1 | 435 | <4 | - | New, this study |
6(39) | 252 | 916 Phe + CO[Lys + Val + Hty + MeHty + AcSer] | 8.4 | 50 | <4 | 2.6 | [37] |
7(39) | 87 | 808 Ile + CO[Lys + Ile + Hty + MeAla + Phe] | 2.9 | 55 | <25 | 1.5 | [37] |
8(40) | 2733 | 828 (Anabaenopeptin D) | 91.1 | 53 | <3 | - | [10] |
Phe + CO[Lys + Val + Hty + MeAla + Phe] | |||||||
8(44/45) | 3816 | 918 Phe + CO[Lys + Val + Hph + MeHty + MetO] | 63.6 | 100 | <3 | - | [42] |
9(44) | 69 | 900 Ile + CO[Lys + Met + Hph + MeHty + Met] | 2.3 | 60 | <28 | - | [24] |
9(45) | 108 | 858 Phe + CO[Lys + Val + Hph + MeHty + Ser] | 3.6 | 50 | <20 | - | New, this study |
918 Phe + CO[Lys + Val + Hph + MeHty + MetO] | [42] | ||||||
10(51) | 579 | 866 Ile + CO[Lys + Val + Hph + MeHty + AcSer] | 19.3 | 435 | 35 | - | New, this study |
10(52) | 84 | 900 Phe + CO[Lys + Val + Hph + MeHty + AcSer] | 2.8 | 140 | <22 | - | [42] |
13(51) | 741 | 868 Ile + CO[Lys + Val + Hph + MeHty + Met] | 24.7 | 71 | 45 | - | New, this study |
* Sample number(retention time).